ArticleQuantitative imaging in medicine and surgery2026
T2* mapping in magnetic resonance imaging for stratifying the hypoxic microenvironment in pancreatic ductal adenocarcinoma: a preliminary study.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing the understanding of tumor microenvironment through medical imaging based on bibliometric analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T2* mapping provides a noninvasive approach for quantifying tissue oxygenation via the detection of the paramagnetic effects associated with deoxyhemoglobin, with validated correlations to hypoxia in other cancers. However, its application in stratifying hypoxic microenvironments in pancreatic ductal adenocarcinoma (PDAC) remains limited. This preliminary study aimed to evaluate T2* mapping as a quantitative imaging biomarker for hypoxia levels in PDAC in order to offer a potential tool for the noninvasive characterization of the tumor microenvironment and the development of personalized treatment strategies. Methods: This retrospective study enrolled 50 patients with PDAC pathologically confirmed between June 2022 and July 2023. Hypoxia-inducible factor-1α (HIF-1α) expression was used to evaluate PDAC hypoxia levels, and patients were stratified into low and high hypoxia groups. T2* values and other clinicoradiological indicators were compared between the two groups via binary logistic regression analysis. A logistic regression model was built with independent factors related to hypoxia levels. The predictive performance of the model was evaluated with area under the curve (AUC) and leave-one-out cross-validation (LOOCV). The correlation between the PDAC HIF-1α expression and T2* values was assessed via the Spearman rank correlation coefficient, and hypoxia levels were compared with pathological findings. Results: T2* values differed significantly between the low and high hypoxia groups (62.63±3.33 Conclusions: T2* mapping may serve as a noninvasive imaging biomarker for stratifying the hypoxic microenvironment in PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.